L-Cin OZ Oral Suspension is a combination antibiotic formulation containing Levofloxacin 125 mg and Ornidazole 125 mg per 5 ml, designed for the treatment of mixed bacterial and protozoal infections. Levofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis through the formation of toxic metabolites. This synergistic combination is indicated for infections involving susceptible aerobic and anaerobic pathogens, including respiratory tract infections, gastrointestinal infections, genitourinary tract infections, and certain intra-abdominal infections. The oral suspension form facilitates ease of administration, particularly in pediatric and geriatric populations or patients with swallowing difficulties. Dosage should be individualized based on the severity of infection, patient age, renal function, and clinical response, with adherence to prescribed duration critical to prevent resistance development. Caution is advised in patients with known hypersensitivity to fluoroquinolones or nitroimidazoles, and potential side effects include gastrointestinal disturbances, central nervous system effects, and hypersensitivity reactions. L-Cin OZ Oral Suspension should be used under medical supervision with appropriate monitoring for efficacy and adverse events.